FierceBiotech names Confo Therapeutics as one of its “Fierce 15” Biotech Companies of 201923. September 2019|In Portfolio News|By eazee-designstudioConfo Therapeutics today announces that it has been named by FierceBiotech as one of 2019’s Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. Confo Therapeutics is building a portfolio of new medicines based on its proprietary Confo® technology. The technology makes use of antibody fragments or “ConfoBodiesTM” to stabilize G-protein coupled receptors (GPCRs) in their functional conformation, providing a superior starting point for drug design. PrevNext
